Background: Homoarginine, a basic amino acid and analogue of L-arginine, has been shown to exert salutary effects on vascular homoeostasis, possibly through interaction with the enzymes nitric oxide synthase and arginase. This might translate into improved survival outcomes, particularly in subjects with moderate-high cardiovascular risk. We conducted a systematic review and meta-analysis to investigate the association between circulating homoarginine concentrations and allcause mortality in observational studies of human cohorts. Materials and methods: Studies reporting baseline circulating homoarginine concentrations and all-cause mortality as outcome were searched using the MED-LINE, Scopus and Cochrane databases until January 2018. Hazard ratios (HRs) with 95% confidence intervals (CIs) derived from multivariate Cox's proportionalhazards analysis were extracted from individual studies. Results: A total of 13 studies in 11 964 participants were included in the final analysis. Homoarginine concentrations were inversely associated with all-cause mortality (HR 0.64, 95% CI 0.57-0.73). This association remained significant in participant sub-groups with predominant cardiovascular disease (HR 0.64, 95% CI 0.55-0.76) and renal disease (HR 0.60, 95% CI 0.46-0.68).
dysfunction, assessed using established noninvasive techniques, is a strong and independent predictor of atherosclerotic cardiovascular events in human studies. 3 Therefore, the identification of endogenous factors and drugs that exert salutary effects on endothelial function remains a priority in cardiovascular research. 4, 5 There is emerging evidence that homoarginine, a basic amino acid that is synthesized from L-arginine by the enzyme arginine:glycine amidinotransferase, exerts beneficial effects not only on endothelial function but also on markers of vascular homoeostasis and cardiac function. [6] [7] [8] [9] [10] Although it has been speculated that the protective effects of homoarginine are at least partly mediated by its interactions with NO synthase and arginase, 2 key enzymes in the L-arginine and NO metabolic pathways, resulting in increased NO synthesis, 6 ,11 significant uncertainty still exists regarding its exact biological effects. 12, 13 Circulating homoarginine concentrations have shown inverse associations with surrogate markers of vascular and cardiac dysfunction. [14] [15] [16] [17] [18] Therefore, one can hypothesize that higher homoarginine concentrations might translate into better clinical outcomes in subjects with various degrees of cardiovascular risk.
A number of observational studies have recently investigated the association between homoarginine concentrations and adverse clinical outcomes. We conducted a systematic review and meta-analysis to study the association between circulating homoarginine concentrations and all-cause mortality in observational studies of human cohorts, including patients with similar disease phenotypes.
| METHODS

| Search strategy, eligibility criteria and study selection
We conducted a literature search, using the terms "homoarginine" and "mortality or survival", by accessing the MEDLINE, Scopus and Cochrane databases, from their inception to the 15 th of January 2018, to identify studies investigating the association between homoarginine concentrations and all-cause mortality. The MEDLINE database was searched using PubMed. Hand searching the citation lists of relevant articles was also performed to identify additional papers. The meta-analysis was conducted according to the PRISMA guidelines. 19 Inclusion criteria for study inclusion were the following: (i) full-text article was available, (ii) article was written in English, (iii) study investigated the association between serum/plasma homoarginine concentrations and all-cause mortality as a specific outcome, (iv) the follow-up was ≥6 months and (v) the study reported hazard ratio (HR) with 95% confidence intervals (CI) for homoarginine-associated all-cause mortality using multivariate Cox's proportional-hazards analysis. Relevant studies were excluded if the above inclusion criteria were not fulfilled.
| Quality scores of included studies
Data from selected studies were independently extracted by 2 investigators (AAM and AZ) and validated by a third investigator (PP). We used the Newcastle-Ottawa Scale (NOS) to assess the quality of each study. The NewcastleOttawa scale evaluates the following components: selection of the study groups, comparability of groups and assessment of the outcome of interest for cohort studies. 20 Studies achieving a score of 6 or more were considered to be of high quality.
| Statistical analysis
Inter-rater agreement of quality scores was assessed by calculating Cohen kappa's coefficient. Meta-analysis was performed using STATA 14 (STATA Corp, College Station, TX, USA). The pooled effect of homoarginine as predictor of all-cause mortality was calculated as HR with 95% CI. Heterogeneity of HR across studies was tested using the Q statistic (significance level at P < .10). The I 2 statistic, a quantitative measure of inconsistency across studies, was also calculated (I 2 < 25%, no heterogeneity; I 2 between 25% and 50%, moderate heterogeneity; I 2 between 50% and 75%, large heterogeneity; and I 2 > 75%, extreme heterogeneity). Sensitivity analysis was conducted to investigate the influence of an individual study on the overall risk estimate, by sequentially excluding 1 study at a time.
To evaluate the presence of potential publication bias, the associations between study size and magnitude of effect were analysed by means of Begg's adjusted rank correlation test and Egger's regression asymmetry test at the P < .05 level of significance. 21, 22 We also performed the Duval and Tweedie "trim and fill" procedure to further assess the possible effect of publication bias. This method considers the possibility of hypothetical "missing" studies that might exist and recalculates a pooled HR that incorporates the hypothetical missing studies as although they actually existed. 23 
| RESULTS
A total of 42 studies were identified through database search. After the abstracts of these studies were screened, 22 reports were excluded because they did not meet the inclusion criteria, leaving 20 records (Figure 1 ). After evaluating the full-text documents of these 20 studies, 7 studies were excluded for the following reasons: 5 did not report specific all-cause mortality outcomes, 1 did not follow-up study participants for ≥6 months, and 1 measured homoarginine in urine but not in serum/plasma ( Figure 1 ). We identified 13 eligible studies for the final analysis. Table 1 describes specific information of the 13 studies meeting the inclusion criteria and included in the meta-analyses. [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Eight studies were conducted in participants with predominant cardiovascular disease, 25, 27, 29, 30, [32] [33] [34] [35] 4 were conducted in participants with predominant renal disease (chronic kidney disease or post-renal transplant), 24, 28, 31, 36 whereas 1 investigated subjects with liver disease. 26 Participant age ranged between 43.0 and 83.9 years, and study follow-up ranged between 2.2 and 9.9 years. Survival data, presented either as Kaplan-Meier or as Nelson-Aalen curves, were provided in 8 studies. [24] [25] [26] 28, 30, 32, 33, 36 Homoarginine was measured in plasma in 7 studies 24, 25, [29] [30] [31] [32] [33] and in serum in 6 studies, 26-28,34-36 using gas chromatographymass spectrometry in 1 study (GC-MS), 24 liquid chromatography-mass spectrometry (LC-MS) in 5 studies 25, 29, [31] [32] [33] and liquid chromatography with fluorescent detection (LC-FLR) in 7 studies. [26] [27] [28] 30, [34] [35] [36] All studies
were of high quality (Cohen Kappa's coefficient = 0.755).
| Homoarginine concentrations and all-cause mortality
The 13 studies included in the meta-analysis provided HR with 95% CI values for the pooled predictive effect of homoarginine on all-cause mortality. Homoarginine concentrations were independently, and inversely, associated with all-cause mortality (HR 0.64, 95% CI 0.57-0.73, P < .0001, Figure 2 ). Due to the high heterogeneity between studies (I 2 = 69.9%, P < .0001), random-effects models were used. The robustness of the estimate was examined by sequentially removing each study and reanalysing the remaining datasets. The corresponding pooled HRs were not substantially altered when single studies were removed, suggesting that the results of the meta-analysis were stable ( Figure S1 ). Evidence of publication bias was provided by a funnel plot (Egger test, P = .006; Begg test, P = .127; Figure S2 ) although trim-and-fill analysis found that no study was missing or should be added.
| Additional analyses
To identify the sources of heterogeneity and publication bias, we investigated the effects of different study characteristics, including predominant disease phenotype (cardiovascular disease vs renal disease), sample size, follow-up period, publication year, age, sex, biological sample (plasma or serum) and detection method used (MS or FLR) through univariate meta-regression. In our analyses, sample size (t = 0.04, P = .966), follow-up period (t = À0.05, P = .961), publication year (t = 0.84, P = .421) and sex (t = À0.32, P = .753) were not related to the pooled HR by meta-regression analysis. The pooled HR value in studies of participants with predominant renal disease (0.60, 95% CI 0.46-0.68, P < .0001; I 2 = 53.5%, P = .091) was lower than that in participants with predominant cardiovascular disease (0.64, 95% CI 0.55-0.76, P < .0001; I 2 = 77.1%, P < .0001) although the difference was not significant (t = 0.43, P = .679, Figure 3 ). Conversely, age (t = À2.35, P = .041, Figure S3 ), biological sample type (t = À2.61, P = .02) and detection method (t = À4.46, P = .001) were related to the HR, suggesting an important effect of these factors on both heterogeneity and publication bias. In particular, the pooled HR from studies measuring homoarginine in plasma (0.74, 95% CI 0.67-0.83, P < .0001; I 2 = 45.4%, P = .09) was significantly higher than that in studies measuring homoarginine in serum (0.57, 95% CI 0.48-0.66, P < .0001; I 2 = 26.0%, P = .24, Figure 4 ). Furthermore, the pooled HR from studies F I G U R E 2 Forest plot depicting the association between homoarginine concentrations and all-cause mortality for all study participants using random-effects model F I G U R E 3 Forest plots depicting the association between homoarginine concentrations and all-cause mortality in studies of participants with cardiovascular disease and in studies of participants with renal disease using random-effects model measuring homoarginine by LC with MS detection was significantly higher (0.77, 95% CI 0.69-0.86, P < .0001; I 2 = 37%, P = .175) than that of studies measuring homoarginine by LC with FLR detection (0.56, 95% CI 0.48-0.64, P < .0001; I 2 = 14.1%, P = .322, Figure 5 ). In both cases, heterogeneity in sub-groups was markedly lower. To further investigate the effect of age on publication bias and heterogeneity, we performed a meta-analysis on a subgroup of studies (n = 7) of patients aged between 50 and 70 years. Forrest plot of these studies ( Figure S4 ) showed a pooled HR of 0.62 (95% CI 0.53-0.73, P < .0001) with a substantially lower heterogeneity (I 2 = 47.9%, P = .07).
Analysis of bias in this sub-group of studies indicated the absence of publication bias (Egger test P = .1; Begg test P = .5).
| DISCUSSION
Our meta-analysis showed a significant inverse association between circulating homoarginine concentrations and allcause mortality. This association remained significant in F I G U R E 4 Forest plots depicting the association between homoarginine concentrations and all-cause mortality in studies measuring homoarginine in serum and in studies measuring homoarginine in plasma using random-effects model
F I G U R E 5
Forest plots depicting the association between homoarginine concentrations and all-cause mortality, in studies measuring homoarginine by liquid chromatography using mass spectrometry detection methods and in studies measuring homoarginine by liquid chromatography using fluorometric detection methods, using random-effects model sub-group analyses according to predominant disease phenotype (cardiovascular vs renal disease), biological sample used for homoarginine measurement (plasma vs serum) and method of detection (mass spectrometry vs fluorescent detection). Age, biological sample type and detection method had an important effect on both heterogeneity and publication bias. Although the publication bias represents a potential limitation of our meta-analysis, it is important to emphasise that the heterogeneity was significantly reduced, and the publication bias was absent, in the sub-group of studies in patients aged between 50 and 70 years, while the pooled HR remained essentially unchanged. Furthermore, all studies included in the meta-analysis were of high quality. Despite major advances in diagnosis and treatment, atherosclerotic cardiovascular disease remains the leading cause of death in the world. 37 Notably, a significant number of cardiovascular events, primarily myocardial infarction and ischaemic stroke, are not fully explained by conventional risk factors, such as hypertension, hypercholesterolaemia and diabetes. 38 Furthermore, many patients receiving optimal secondary pharmacological prevention therapy after an acute event will suffer from recurrent events over time. 39, 40 Therefore, there is a continuing search for novel biomarkers to improve risk stratification and to identify more effective therapeutic strategies. An increasing amount of evidence suggests that homoarginine, an endogenous analogue of the amino acid L-arginine, might represent a useful cardiovascular risk biomarker. Although there is considerable uncertainty regarding the exact mechanisms involved in its putative protective effects, it has been suggested that homoarginine might be, similarly to L-arginine, a substrate for NO synthase and an inhibitor of the enzyme arginase. 41, 42 Arginase inhibition would increase the availability of the substrate L-arginine for NO synthase, resulting in a further increase in NO synthesis and, hence, anti-atherosclerotic effects. 1 Other studies have shown that homoarginine reduces citrulline formation by NO synthase. However, the concentrations of homoarginine shown to be a substrate for NO synthase, or to inhibit NO synthase activity, were significantly higher than the observed physiological concentrations (1-10 lmol/L). 12, 41, 42 Furthermore, the biological and clinical significance of arginase inhibition by homoarginine has been recently challenged. Tommasi et al 13 showed that both human arginase isoforms, 1 and 2, retained 90% activity in the presence of physiological homoarginine concentrations (1-10 lmol/L). Recent studies have investigated cross-sectional associations between homoarginine concentrations and markers of vascular/metabolic homoeostasis and cardiac function. Haghikia et al 14 reported nonsignificant associations between plasma homoarginine concentrations and aortic distensibility and intima-media thickness in 78 patients with a recent cerebrovascular event. Pilz et al 15 observed significant inverse associations between serum homoarginine concentrations and N-terminal pro-B-type natriuretic peptide (P < .001) and midregional pro-adrenomedullin (P < .001), biomarkers of diastolic dysfunction and heart failure, in 1396 patients with preserved left ventricular ejection fraction. Krebs et al 16 showed that plasma homoarginine concentrations were inversely associated with glycated haemoglobin (P < .001) in 28 children with type 1 diabetes. van der Zwan et al 17 observed significant inverse associations between plasma homoarginine concentrations and systolic (P < .001) and diastolic (P < .001) blood pressure in 746 older adults. Valtonen et al 18 demonstrated a positive and significant correlation between serum homoarginine concentrations and flow-mediated dilatation of the brachial artery (P = .022), a marker of endothelial function, in 58 pregnant women. Recently, a longitudinal study has also sought to investigate whether serum homoarginine concentrations predicted the development of cardiometabolic risk factors. Sepp€ al€ a et al 43 in a population of 2106 young adults followed for 10 years, showed that homoarginine predicted hyperglycaemia (OR 1.31, 95% CI 1.06-1.63) and abdominal obesity (OR 1.60, 95% CI 1.14-2.30) in males and type 2 diabetes (OR 1.55, 95% CI 1.02-2.41) in females. However, using summary-level data from available meta-analyses of genome-wide association studies, the authors observed no significant relationships between 3 single-nucleotide polymorphisms, associated with serum homoarginine concentrations, and cardiometabolic risk factors, type 2 diabetes mellitus and coronary artery disease.
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Our meta-analysis identified 13 high-quality observational studies that were conducted in patients with predominant cardiovascular disease and renal disease, barring 1 study in patients with advanced liver disease. Despite the high heterogeneity between studies, a significant inverse association between circulating homoarginine concentrations and all-cause mortality was demonstrated when all studies were taken together, and in sub-group analysis of patients with predominant cardiovascular or renal disease phenotypes. Because the detection and measurement of small molecules such as homoarginine might be influenced by specific biological matrices and/or analytical detection methods, we conducted further analyses and demonstrated that, although the inverse association between homoarginine and mortality was maintained, the pooled HR from studies measuring plasma was significantly higher than that in studies measuring serum. Furthermore, the pooled HR from studies using MS detection techniques was significantly higher than that of studies using FLR detection techniques. Although these factors might influence the interpretation of the biological and clinical role of homoarginine in risk stratification, the exact causes for the reported differences are uncertain at present and require further research.
Studies have also investigated the effects of homoarginine supplementation on surrogate markers of vascular and cardiac function in animal models. Atzler 16-week oral homoarginine supplementation in rats significantly prevented the increase in serum glucose concentrations during a high-fat diet. In this study, homoarginine supplementation, particularly at high dose, was also associated with significantly higher concentrations of plasma insulin, C-peptide and leptin concentrations during high-fat diet. Taken together, the results of cross-sectional and interventional studies support the hypothesis that homoarginine might favourably affect vascular and cardiac homoeostasis. Pending confirmation in further studies, the strong and independent association observed between circulating homoarginine concentrations and mortality not only suggests that homoarginine might represent a novel biomarker of risk but also raises the possibility that interventions affecting homoarginine concentrations might favourably affect clinical outcomes. Although homoarginine supplementation studies have been generally conducted in animals, Atzler et al 44 have recently demonstrated the feasibility and safety of acute and chronic oral homoarginine supplementation in humans. In this study, homoarginine supplementation, 125 mg/d, was associated with a significant increase in plasma homoarginine concentrations (baseline concentration: 2.87 AE 0.91 lmol/L; C max after a single dose: 8.74 AE 4.46 lmol/L; C max after 4 weeks: 17.3 AE 4.97 lmol/L). These results support the feasibility of randomized controlled trials investigating the effects of acute and/or chronic homoarginine supplementation on cardiovascular risk as well as "hard" clinical outcomes such as cardiovascular morbidity and cardiovascular and allcause mortality in different patient populations. Strengths of our study include the assessment of an objective outcome (all-cause-mortality), which was captured by accessing electronic records and national databases in all studies, and the sub-group analysis of factors potentially influencing the pooled HR as well as the between-study heterogeneity. The study limitations include the relatively low number of studies included in the final analysis and the lack of assessment of additional clinical end-point. Although several studies assessed cardiovascular morbidity and mortality, there were significant between-study differences in the criteria used to adjudicate these outcomes. Therefore, a further meta-analysis of cardiovascular morbidity and mortality was not considered practical.
In conclusion, our meta-analysis provides strong evidence that higher circulating homoarginine concentrations are associated with reduced all-cause mortality, particularly in patients with cardiovascular and renal disease. Further research is warranted to identify the mechanisms responsible for the beneficial effects of homoarginine on vascular and cardiac function, to investigate the associations between homoarginine and clinical outcomes in other patient populations, and to study the effects of homoarginine supplementation on such outcomes.
